We provide you with 20 years of free, institutional-grade data for BHVN stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of BHVN. Explore the full financial landscape of BHVN stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Biohaven Pharmaceutical Holding Co Ltd. | Initial | 2022-09-28 | |||
| Bailey Gregory | Open Market Purchase | 38,000 | $148.04 | 2022-08-22 | |
| Clark George C. | Initial | 2021-08-13 | |||
| Mehta Kishan | Initial | 2021-06-17 |
The information provided in this report about BHVN stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Biohaven Pharmaceuticals(NYSE:BHVN) 
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive t...
Website: http://www.biohavenpharma.com
Founded: 2013
Full Time Employees: 647
CEO: Vlad Coric
Sector: Healthcare
Industry: Biotechnology